BAY-342
- Generic Name
- BAY-342
A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause
- Conditions
- Sleep Disturbances Associated With Menopause
- Interventions
- Other: Placebo
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Bayer
- Target Recruit Count
- 110
- Registration Number
- NCT06112756
- Locations
- 🇩🇪
Siteworks - Zentrum für klinische Studien Hannover, Hannover, Niedersachsen, Germany
🇺🇸MomDoc Women's Health Research | Scottsdale, AZ, Scottsdale, Arizona, United States
🇺🇸Preferred Research Partners, Little Rock, Arkansas, United States
A Study to Learn How Different Levels of Decreased Liver Function Influence Blood Levels of Elinzanetant Compared to Normal Liver Function in Male and Female Participants
- Conditions
- Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
- Interventions
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 33
- Registration Number
- NCT04903821
- Locations
- 🇩🇪
CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany
🇩🇪APEX GmbH, München, Bayern, Germany
Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms
- Conditions
- Post-menopausal Vasomotor Symptoms
- Interventions
- Drug: Placebo (for BAY3427080)
- First Posted Date
- 2016-08-12
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 76
- Registration Number
- NCT02865538
- Locations
- 🇺🇸
QPS/MRA (Miami Clinical Research), Miami, Florida, United States
🇺🇸Avail Clinical Research, DeLand, Florida, United States
🇺🇸ICON Clinical Research Unit, San Antonio, Texas, United States
First Time in Human Study (FTIH) With Positron Emission Tomography (PET)
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 21
- Registration Number
- NCT01381419
- Locations
- 🇬🇧
GSK Investigational Site, Harrow, Middlesex, United Kingdom
A Repeat Dose Positron Emission Tomography Study With GSK1144814
- First Posted Date
- 2010-09-24
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 41
- Registration Number
- NCT01209039
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy Subjects
- First Posted Date
- 2010-03-22
- Last Posted Date
- 2017-06-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 16
- Registration Number
- NCT01090440
- Locations
- 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.